View Older Stories View More Recent Stories
-
Leerink Partners on Illumina (ILMN), 'optics is likely to affect customer willingness to buy'
-
Illumina slides as China bans imports of its gene sequencers
-
China Bans Illumina (ILMN) Sequencer Imports
-
Citi Opens 90-Day Downside Short-term View on Illumina (ILMN)
-
HSBC Downgrades Illumina (ILMN) to Hold
-
Illumina (ILMN) transforms multiomic research with new technologies to unlock deeper understanding of biology
-
Illumina (ILMN) and Broad Clinical Labs usher in new era of drug discovery with collaboration to rapidly scale single-cell solutions
-
TD Cowen Reiterates Hold Rating on Illumina (ILMN)
-
Illumina (ILMN) unveils first-of-its-kind spatial transcriptomics technology
-
Morgan Stanley sees continued risk for this biotech stock
-
Barclays Downgrades Illumina (ILMN) to Underweight
-
RBC on Illumina (ILMN): 'A Stock To Own For Multiple Investment Strategies'; PT Lowered to $247
-
TD Cowen Downgrades Illumina (ILMN) to Hold
-
Illumina (ILMN) PT Lowered to $135 at Canaccord Genuity
-
Illumina (ILMN) Tops Q4 EPS by 3c, provides guidance
-
Illumina (ILMN) call put ratio 3.4 calls to 1 put into quarter results
-
Illumina (ILMN) call put ratio 1 call to 1.3 puts as share price down 6.5%
-
China Adds Pvh Group, Illumina Inc To Unreliable Entity List - Bloomberg
-
Illumina (ILMN) Reports Prelim Q4 Results, Offers FY25 Guidance
-
Illumina (ILMN) and NVIDIA collaborate to decode biology and propel precision health
-
Illumina (ILMN) and Ovation.io Collaborate to Advance Genomic Data Research
-
Palantir (PLTR), MicroStrategy (MSTR), and Axon (AXON) to join NASDAQ 100
-
Citi Downgrades Illumina (ILMN) to Neutral
-
Super Micro Computer (SMCI) CEO Says He Is Confident The Company's Stock Won't Be Delisted From Nasdaq - Reuters
-
Palantir (PLTR), Microstrategy, Inc. (MSTR) Likely to Join Nasdaq 100 as Moderna (MRNA) Exists - Bloomberg Intelligence
-
Illumina (ILMN) announces expansion of TruSight Oncology portfolio
-
Illumina (ILMN) PT Raised to $184 at Stephens
-
Morgan Stanley Resumes Illumina (ILMN) at Equalweight
-
Illumina (ILMN) PT Raised to $139 at Baird
-
Illumina (ILMN) PT Raised to $177 at TD Cowen
-
Illumina (ILMN) PT Raised to $145 at Canaccord Genuity
-
Piper Sandler Reiterates Overweight Rating on Illumina (ILMN)
-
Illumina (ILMN) PT Raised to $145 at Barclays
-
Illumina (ILMN) PT Raised to $190 at Citi
-
Illumina (ILMN) Tops Q3 EPS by 26c; offers guidance
-
Illumina (ILMN) call put ratio 2.9 calls to 1 put with focus on January 165 calls as share price up 3.2%
-
HSBC Upgrades Illumina (ILMN) to Buy
-
TD Cowen Reiterates Buy Rating on Illumina (ILMN)
-
Piper Sandler Reiterates Overweight Rating on Illumina (ILMN)
-
Baird Reiterates Neutral Rating on Illumina (ILMN)
-
Canaccord Genuity Reiterates Hold Rating on Illumina (ILMN)
-
BofA Securities Reiterates Underperform Rating on Illumina (ILMN)
-
Leerink Partners Reiterates Outperform Rating on Illumina (ILMN)
-
Citi Reiterates Buy Rating on Illumina (ILMN)
-
Illumina (ILMN) introduces the MiSeq i100 Series
-
Illumina (ILMN) Files Mixed Shelf
-
European Court of Justice rules in favor of Illumina (ILMN) in jurisdictional appeal
-
GRAIL, Inc. (GRAL): Results of Galleri Multi-Cancer Early Detection Blood Test in Prostate Cancer Published in JCO Precision Oncology
-
Illumina (ILMN): FDA approves cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies
-
3 ways to gain stock market exposure to the fertility theme
